

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Glioblastoma multiforme (GBM)	CD95 ligand (CD95L); CD95; Yes; phosphoinositide 3-kinase (PI3K); glycogen synthase kinase 3 β (GSK3 β)	A study in cell culture, mice and human clinical isolates suggests that antagonizing CD95L, CD95 or its downstream effectors could help treat GBM. Blocking CD95L or downstream effectors of CD95, such as the Src family kinase Yes and PI3K, reduced glioblastoma invasiveness and migration through collagen matrices compared with control tumors that were untreated or received isotype antibody. Next steps include identifying mAbs or small molecules that selectively block CD95 and CD95L activation or the recruitment of Yes and PI3K to activated CD95. Apogenix GmbH is developing CD95L therapeutics to treat GBM.	Patented and licensed to Apogenix GmbH	Kleber, S. <i>et al. Cancer Cell</i> ; published online March 13, 2008; doi:10.1016/j.ccr.2008.02.003 Contact: Ana Martin-Villalba, University of Heidelberg, Heidelberg, Germany e-mail: a.martin-villalba@dkfz.de